Geoffrey Potts, MD
Dermatology · Troy, MINPI 1598052441
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,961 of the $10,517 with a category attached, or 75.7%. 40 manufacturers reported payments, led by Pfizer at 27.7% of the total. Reporting peaked in 2019 at $2,479 and has fallen 65.0% since, to $868 in 2025.
Across 326 payments — averaging $32.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- AbbVie$2K
- Johnson & Johnson$2K
- Novartis$589
- Regeneron Healthcare Solutions, Inc.$459
- UCB, Inc.$425
- plus $3K from 34 others
Across 157 payments — averaging $1480.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$141K
- Regeneron$64K
- Incyte Corporation$20K
- Eli Lilly$8K
What the payments were for
- Consulting fees$8008%
- Travel & lodging$1,60215%
- Food & beverage$7,96176%
- Education$1551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $2,918 |
| AbbVie | 59 | $2,014 |
| Johnson & Johnson | 58 | $1,570 |
| Novartis | 38 | $589 |
| Regeneron Healthcare Solutions, Inc. | 20 | $459 |
| UCB, Inc. | 15 | $425 |
| LEO Pharma Inc. | 21 | $406 |
| Sanofi | 15 | $288 |
| Lilly USA, LLC | 12 | $228 |
| Galderma Laboratories, L.p. | 13 | $209 |
| Genentech USA, Inc. | 10 | $182 |
| Mallinckrodt Enterprises LLC | 1 | $99 |
| Boehringer Ingelheim | 4 | $95 |
| E.r. Squibb & Sons, L.L.C. | 5 | $93 |
| Amgen | 5 | $84 |
| Fresenius Kabi USA, LLC | 3 | $79 |
| Kerecis Limited | 1 | $66 |
| Merck | 2 | $62 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Dermira, Inc. | 2 | $50 |
| Kyowa Kirin, Inc. | 2 | $49 |
| Mylan Institutional Inc. | 2 | $47 |
| Incyte Corporation | 2 | $45 |
| Helsinn Therapeutics (U.S.), Inc. | 3 | $43 |
| Organogenesis Inc. | 2 | $41 |
| Dermavant Sciences, Inc. | 2 | $37 |
| Teleflex LLC | 2 | $35 |
| Krystal Biotech Inc | 2 | $29 |
| VYNE Pharmaceuticals Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| Organon | 1 | $23 |
| 180 Medical, Inc. | 1 | $22 |
| Hartmann USA, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| Acera Surgical, Inc. | 1 | $15 |
| Mimedx Group, Inc. | 1 | $15 |
| Biofrontera Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,517 in reported general payments places this provider in the 85th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 50 | $614,213 |
| Skyrizi PenRisankizumab-Rzaa | 15 | $338,373 |
| Dupixent PenDupilumab | 48 | $178,155 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 18 | $150,031 |
| Cosentyx Unoready PenSecukinumab | 15 | $132,366 |
| Clobetasol Propionate | 87 | $5,305 |
| Betamethasone Dipropionate | 93 | $2,785 |
| Ketoconazole | 127 | $2,345 |
| Glycopyrrolate | 21 | $1,658 |
| Calcipotriene | 12 | $1,377 |
| Tacrolimus | 18 | $1,144 |
| Metronidazole | 18 | $1,143 |
| Triamcinolone Acetonide | 72 | $1,069 |
| Ammonium Lactate | 64 | $939 |
| Clindamycin Phosphate | 29 | $523 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Troy
- George MurakawaTroy$192K
- Ann HernTroy$118K
- Ali MoiinTroy$29K
- Farah MalickTroy$17K
- Linda Stein GoldWest Bloomfield$3.3M
- Kristi HawleyCaledonia$2.2M
- David AltmanWarren$1.9M
- Michael SiegelWaterford$708K
- Johann GudjonssonAnn Arbor$535K
- Michael DormanWest Bloomfield$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.